Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma?

F. McClanahan; T. Hielscher; M. Rieger; M. Hensel; M. Bentz; I. Schmidt-Wolf; A. Kbisch; H. Salwender; H. Dürk; H. Staiger; T. Mandel; K. Neben; J. Hillengass; E. Leo; A. Krmer; A.D. Ho; M. Witzens-Harig

首页> 外文期刊>AMERICAN JOURNAL OF HEMATOLOGY >Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma?

【24h】

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma?

机译：比较1次，3次或6次利妥昔单抗输注加6个周期CHOP的随机试验的最终结果，为更经济，更安全地治疗晚期滤泡性淋巴瘤提供了有价值的初步数据。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

No abstract is available for this article.

机译：本文没有摘要。

著录项

来源
《AMERICAN JOURNAL OF HEMATOLOGY》 |2012年第10期|E68-E71|共4页
作者
F. McClanahan; T. Hielscher; M. Rieger; M. Hensel; M. Bentz; I. Schmidt-Wolf; A. Kbisch; H. Salwender; H. Dürk; H. Staiger; T. Mandel; K. Neben; J. Hillengass; E. Leo; A. Krmer; A.D. Ho; M. Witzens-Harig;
展开▼
作者单位

Internal Medicine V University of Heidelberg Heidelberg Germany;

Centre for Haemato-Oncology Barts Cancer Institute Queen Mary University of London Charterhouse Square London United Kingdom;

Department of Biostatistics German Cancer Research Centre Heidelberg Germany;

Onkologische Schwerpunkt Praxis Mannheim Germany;

Onkologische Schwerpunkt Praxis Mannheim Germany;

City Hospital Karlsruhe Medicine II Karlsruhe Germany;

Medicine I University Hospital Bonn Bonn Germany;

Facharztpraxis Internal Medicine Gieβen Germany;

Asklepios Klinik Altona Medicine II Hamburg Germany;

St. Marien-Hospital Hamm Hamm Germany;

Klinikum Mittelbaden City Hospital Baden-Baden Germany;

SLK Kliniken Heilbronn Medicine II Bad Friedrichshall Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献

1. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: SWOG S0016 [J] . PressO.W., UngerJ.M., RimszaL.M., Journal of Clinical Oncology . 2013,第3期

机译：CHOP加利妥昔单抗与CHOP化疗加131碘-tositumomab进行的先前未经治疗的滤泡性非霍奇金淋巴瘤的III期随机对照试验：SWOG S0016
2. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03 [J] . Taverna Christian, Martinelli Giovanni, Hitz Felicitas, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Rituximab维持治疗在滤泡淋巴瘤最多5年：随机阶段III试验SAKK 35/03的最终结果
3. Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. [J] . Umberto Vitolo, Marco Ladetto, Carola Boccomini, Journal of Clinical Oncology . 2013,第27期

机译：利妥昔单抗维持率与60岁以上晚期滤泡性淋巴瘤患者进行简短的一线R-FND化疗联合利妥昔单抗巩固治疗后的观察结果比较：Fondazione Italiana Linfomi进行的III期随机研究。
4. Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016 [O] . Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, -1

机译：CHOP加利妥昔单抗与CHOP化学疗法加131碘-托西单抗治疗先前未治疗的滤泡性非霍奇金淋巴瘤的III期随机分组研究：SWOG S0016
5. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma [O] . F. McClanahan, T. Hielscher, M. Rieger, 2012

机译：随机试验的最终结果比较1,3或6个rituximab加6个循环剁为更具成本效益和更安全的卵泡淋巴瘤的治疗提供了有价值的初步数据

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma?

摘要

著录项

相似文献

相关主题

期刊订阅